Tag Archives | molecular diagnostics

J.P.Morgan Conference #2: Red Screen Distracts Biotech Investors…Update

Green Screen Alert Market Update…IBB up 4% today erasing most of Wednesday’s Losses but we are still down 13.86% for the five day period. Nasdaq rallied 1.97%. Rayno Biopharma top winners: ABBV up 6.56%, ALXN up 5.93%, AMGN up 5.29%,BIIB up 4.98%, REGN up 4.25%,RXDX up 8.96%, SGEN up 2.26% and VRTX up 5.75%. Most […]

Continue Reading 0

Biotech Rally Gains Momentum…Update-1

Update-1 Rayno Recap for week of 11/20/15 IBB up 3.04%, XBI  up 1.92%,  XLV up 2.82% Notable Small Cap Winners Curis (CRIS) up 4.13%, Fibrocell Sciences (FCSC) up 3.42%, Geron (GERN) up 4.82%, Ignyta (RXDX) up 37.39%, and Ocera Therapeutics (OCRX) up 5.31%. Notable Rayno Dx and Tools Winners Cepheid (CPHD) up 6.45%, Illumina (ILMN) […]

Continue Reading 0

Rayno Tools and Molecular Diagnostics: Looking For Value

Looking for Value in a Slow Growth Market Life Science stocks took a big hit over the past summer and many have not fully recovered.The important metric to watch is sales growth because many of the smaller cap companies are still lagging in earnings growth so the PE tells you very little. The major technology […]

Continue Reading 0

Large Cap Biotech Stocks Get Traction From Revenue Growth…Update-1

10/29/15 Update Large Cap Biotechs Update Amgen (AMGN) Revenues Grow 14%, beats street. 2016 Revenues guided to ~$22B, flattish revenue growth with higher EPS $10.35-$10.75. 2015 PEG=1.80, P/S=5.94, Div. 1.94% Rayno Biopharmaceutical Portfolio Large Caps up 2.6% YTD, IBB up 8% YTD REGN up 37%, GILD up 16%, AMGN up o.6% ABBV ALXN BIIB RHHBY […]

Continue Reading 0

Slower Growth in Diagnostics Stocks Except for NexGen Sequencing and Molecular

New technologies in diagnostics and tools are driving growth: NexGen sequencing, molecular and “point-of-care” testing platforms and veterinary testing. M&A and consolidation should continue. The sector is a laggard due to slowing  sales and earnings growth vs forecasts. Rayno Clinical Diagnostics Portfolio Update We initiated coverage of Clinical Diagnostic and Life Science Tools stocks in […]

Continue Reading 0

Rayno Life Sciences DX and Tools Update: 2015 Q1 Winners ALR,FMI,HOLX

Diagnostic Stocks rally with NASDAQ and Small Caps –IWM Up 1.66% Life Science Tools and Diagnostics stocks are a tad off their one year highs hit by dollar strength and disappointing revenue growth in some cases. Sequencing stocks were big winners but sold off after the JPMorgan Conference. Nonetheless the sector is attractive longer term […]

Continue Reading 0

Rayno Dx and Tools: Update EXAS

Valuation Does Matter If Revenue Growth Slows Last week we posted a YTD summary of our diagnostics and tools focus stocks. Three stocks that are up over one year but have been weak in 2015. We said that revenue guidance and technicals will be important for: Exact Sciences (EXAS), Genomic Health (GHDX) and Neogen (NEOG). […]

Continue Reading 0

Rayno Dx and Tools: 2015 Q1 Mid Quarter Update-FMI, CSII, HOLX, ALR

Bullish Trend Continues for Mid-Cap Growth Stocks The Life Science Tools and Clinical Diagnostics sector kept pace with major life science ETF performance. Major  ETFs (FBT,IBB,XBI) are up about 10% YTD and our top performers are up over 10%. We will provide an update of our  Clinical Diagnostics portfolio after all earnings reports are in. […]

Continue Reading 0

Rayno Dx and Tools Portfolio: CSII HOLX ILMN TMO Stellar Performers

Solid  earnings reports-All of Our Picks Are Strong Holds But Strong Dollar a Factor in 2105 Cardiovascular Systems (CSII) Stock Soars 15% On Strong Revenues Interventional treatments for cardiovascular disease Q2 Revenues soared 38% to $44.7M compared to previous fiscal Q2 2014. Fiscal Q2 2105 loss was $5.3M or (0.17) per share. Hologic (HOLX) Beats […]

Continue Reading 0

JPMorgan Conference #3: Emerging Clinical Dx Companies- AXDX, GNMK

Next Generation Clinical Diagnostic Systems We sat in on presentations for two innovative clinical diagnostic companies that have platform products serving big potential markets. Although it may be early to buy these stocks now they should be on your watch list for the new product revenue ramp up. Solutions For The Global Challenge of Drug […]

Continue Reading 0

Happy New Year 2015!

Wishing you all a Happy and Prosperous New Year! Biotech stocks were up 47% in 2014. In 2014 the first quarter was the most volatile. Sign up now to receive all of our market and portfolio updates. In December we posted updates on our Rayno Life Science Portfolios: Rayno Diagnostics and Tools Part 2: Rayno […]

Continue Reading 0

Rayno Life Science: Market Update 11/26… Stocks Cruise To New Highs

NASDAQ leads -up 0.6% to 4787 The October correction of ~7% was a “headfake” as macro events scared many investor away Technology and Healthcare Stocks Lead The Way The healthcare SPDR (XLV) is up 24.5% YTD and the technology SPDR (XLK) is up 18% YTD. Biotech stocks are at new highs with all major ETFs […]

Continue Reading 0

Rayno Life Science Performance: Up 21%+ YTD…FBT, GILD, ILMN

Biotechs Continue To Lead The Market NASDAQ registered its third day of gains up 2.38% for the period and life science stocks followed. The NAZ is now up 3.34% YTD. Biotech stocks are way ahead of the market  YTD with our top ETF pick (FBT) up 31% YTD and 3.66% over five days.The IBB is […]

Continue Reading 0

Rayno Life Science Stocks: Stealth Rally Ignited By Apple..Update 1

Update -1 Choppy Market Continues..Faux Rally on Wednesday? NASDAQ at 4561 Down 0.66% 1-Reiterate profit taking in Achillion (ACHN), Exact Sciences (EXAS) and  Illumina (ILMN). 2-XBI treading water at 160 since August 26. Bull market intact. 3-Recent early August new buys ran up then fell back: CLDX, KPTI and PACB. 4-ACHN momentum is easing at […]

Continue Reading 0

Biotech Sell-Off On Profit Taking : September Is Here… Update 9/9

Update-1 …Market Continues Sell-Off With QQQs Treading Water in September Follow Technicals on FBT and QQQ. The Federal Reserve continues to be the main concern of investors as the probability of a rate hike looms greater and sooner. Policy officials will meet next week. The Apple (AAPL) rally was whacked after being up over 4% […]

Continue Reading 0